Latest News and Press Releases

CRANBURY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that...

Growing Momentum for EU Galafold (Migalastat) Launch for Fabry Disease Tracking Toward 300 Patients by Year-End 2017  Target Enrollment Achieved in Phase 1/2 Pompe Study – Additional Data...

National Institute for Health and Care Excellence (NICE) Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease CRANBURY, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Amicus...

CRANBURY, N.J., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a...

Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients Biomarker of Key Disease Substrate (Hex4) Demonstrates Improving Trend in All Patients Safety Data...

Scientific Findings Reveal that Cellular Damage Alters Trafficking for Key Proteins Involved in Muscle Membrane Integrity and Muscle Repair Preclinical Studies Demonstrate Reversal of Cellular...

New Phase 3 Retrospective Analysis Shows Correlation between Reduction in Disease Substrate (Kidney Interstitial Capillary GL-3) and Improved Diarrhea in Fabry Patients with Amenable Mutations treated...

CRANBURY, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that...

CRANBURY, N.J., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3...

Strong Momentum for Galafold Launch in Europe and Multiple Global Regulatory Submissions Ahead Additional Data from Pompe Phase 1/2 Clinical Study and Top-Line Data from Phase 3 Epidermolysis...